Phio Pharmaceuticals Corp. (PHIO)
| Market Cap | 3.81M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -10.83M |
| Shares Out | 4.59M |
| EPS (ttm) | -5.20 |
| PE Ratio | n/a |
| Forward PE | 0.31 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,979,398 |
| Open | 0.630 |
| Previous Close | 0.626 |
| Day's Range | 0.610 - 1.050 |
| 52-Week Range | 0.500 - 6.850 |
| Beta | 1.42 |
| Analysts | Strong Buy |
| Price Target | 4.00 (+381.99%) |
| Earnings Date | May 9, 2024 |
About PHIO
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells. The company was formerly known as RXi Ph... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for PHIO stock is "Strong Buy" and the 12-month stock price forecast is $4.0.
News
Intratumoral Injection of Phio's PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells
-Injection in murine tumors shows the compound is well tolerated -Studies support ongoing clinical trial of PH-762 as a neoadjuvant therapy for treatment of cSCC, melanoma, or Merkel cell carcinoma MA...
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)
Phio's lead clinical product candidate, PH-762, is the subject of three new dermatological posters Phio's lead clinical product candidate, PH-762, is the subject of three new dermatological posters
Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)
MARLBOROUGH, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is d...
National Spotlight Features Phio's Innovative RNAi Technology Platform
—Program will be airing on PBS with Dennis Quaid in April —It will also be seen on Fox Business Network MARLBOROUGH, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO)...
Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update
– Four sites across the country participating in clinical trial for lead product candidate PH-762 – Two patients have already completed treatment – New patent granted for skin related treatments, ext...
Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research
MARLBOROUGH, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is d...
Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin Disorders
Phio's Compound RXI-185 and RXI-231 designed to treat photo-aging and hyperpigmentation Phio's Compound RXI-185 and RXI-231 designed to treat photo-aging and hyperpigmentation
Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
--New preclinical data to be presented at Immunotherapy Conference in Germany MARLBOROUGH, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechn...
Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds
MARLBOROUGH, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed ...
Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
MARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed ...
Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas
MARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed ...
Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control
Intratumoral injection of INTASYL self-delivering RNAi compound targeting CTLA-4 (27790) in combination with systemic anti-PD-1 antibody therapy offers a novel approach to combination Immune Checkpoin...
Phio Pharmaceuticals Announces Upcoming Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
MARLBOROUGH, Mass., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed ...
Phio Pharmaceuticals Presents New Data for Targeting of BRD4 with its INTASYL™ Compound PH-894
--Preclinical data shows melanoma cells treated with PH-894 makes them more recognizable to immune cells, increasing potential for elimination
Phio CEO to Speak at Wainwright Conference in New York in September
He'll address clinical trial progress in Phio's lead product candidate He'll address clinical trial progress in Phio's lead product candidate
Phio Pharmaceuticals Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx, Inc. and Providence Cancer Institute
Trial targeting treatment of metastatic melanoma and other solid tumors Trial targeting treatment of metastatic melanoma and other solid tumors
Phio Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
MARLBOROUGH, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed ...
Phio Pharmaceuticals Announces Closing of $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
MARLBOROUGH, Mass. , June 2, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to m...
Phio Pharmaceuticals Announces $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
MARLBOROUGH, Mass. , May 31, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to m...
Phio Pharmaceuticals Announces Initiation of Collaborative Clinical Trial with PH-762, AgonOx's Tumor Infiltrating Lymphocyte Program (AGX148) and Providence Cancer Institute
One of two newly announced clinical trials for its lead product candidate, PH-762 MARLBOROUGH, Mass. , May 24, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechn...
Phio Pharmaceuticals Presents Preclinical Study Showing INTASYL™ Treatment of NK Cells More than Doubles Ability to Kill Tumor Cells
Data is being presented at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting MARLBOROUGH, Mass. , May 18, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical...
Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas
MARLBOROUGH, Mass. , May 16, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to m...
Phio Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
MARLBOROUGH, Mass. , May 11, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to m...
Phio Pharmaceuticals Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
MARLBOROUGH, Mass. , April 20, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to...
Phio Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
MARLBOROUGH, Mass. , April 18, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to...